Barriers to patient enrolment in phase III cancer clinical trials: interviews with clinicians and pharmaceutical industry representatives

OBJECTIVES: Phase III cancer clinical trials are expensive and time-consuming phases in drug development. Effective patient enrolment can reduce delays and save costs, offering patients an opportunity to benefit from innovative treatments. However, the current evidence base does not fully explain th...

Descripción completa

Detalles Bibliográficos
Autores principales: Dane, Aniek, Ashraf, Soedaba, Timmis, James, Bos, Monique, Uyl-de Groot, Carin, van der Kuy, P Hugo M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860011/
https://www.ncbi.nlm.nih.gov/pubmed/35177455
http://dx.doi.org/10.1136/bmjopen-2021-055165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860011/
https://www.ncbi.nlm.nih.gov/pubmed/35177455
http://dx.doi.org/10.1136/bmjopen-2021-055165

Ejemplares similares